Objectives: To compare the needs and issues faced by breast cancer survivors (BCSs) who received chemotherapy as part of their treatment with those who did not and assess satisfaction with a specialist breast care nurse-led survivorship clinic.
Sample & Setting: BCSs who attended a specialist breast care nurse-led survivorship clinic at a Western Australian private, not-for-profit hospital.
Methods & Variables: A multimethod evaluation included surveys, quality-of-life assessments, and reviews of wellness plans.
Results: A total of 68 BCSs participated; the majority had received chemotherapy as part of their treatment and were female. BCSs experienced a diverse range of issues. Significant differences were found between chemotherapy and nonchemotherapy groups for financial difficulties (p = 0.002), body image (p = 0.017), future perspective (p = 0.022), and arm symptoms (p = 0.007). Participants indicated that the specialist breast care nurse-led clinic was appropriately timed and highly valued.
Implications For Nursing: Specialist breast care nurse-led clinics can identify and address BCSs' ongoing needs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1188/23.ONF.753-764 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Breast Cancer Survivors' Diet and Physical Activity Preferences and Barriers: How COVID-19 Changed the Intervention Landscape.
Curr Dev Nutr
January 2025
Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, United States.
Background: Existing studies on breast cancer survivors (BCS) have primarily focused on individual aspects of either diet or exercise preferences and barriers. Our study aims to examine BCS' perceptions toward diet and exercise combined. Given the transformative impact of COVID-19, there is a crucial need for insights in the post-pandemic era to address the distinct challenges faced by BCS in maintaining their health and well-being.
View Article and Find Full Text PDFBreast Suspicious Microcalcifications on Contrast-Enhanced Mammograms: Practice and Reflection.
Int J Gen Med
January 2025
Department of Radiology, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, People's Republic of China.
Purpose: To evaluate the use of contrast enhanced mammography (CEM) in suspicious microcalcifications and to discuss strategies to cope with its diagnostic limitations.
Methods: We retrospectively evaluated patients with suspicious calcifications who underwent CEM at our institution. We collected and analyzed morphological findings, enhancement patterns and pathological findings of suspicious microcalcifications on CEM.
Evaluating YouTube Videos With Prophylactic Mastectomy Content in Terms of Their Quality and Reliability.
Breast J
January 2025
Department of General Surgery, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey.
Purpose of this study is to investigate the quality and reliability of YouTube video contents on prophylactic mastectomy. The search terms "prophylactic mastectomy," "prophylactic mastectomy surgery," "preventive surgery for breast cancer," "risk-reducing mastectomy," and "prophylactic mastectomy and breast reconstruction" were searched on YouTube. The uploader, video content, length (seconds), upload date, number of days since upload date, number of views, number of comments, and likes were recorded and evaluated.
View Article and Find Full Text PDFEfficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
Eur J Cancer
January 2025
Department of Gynecology with Breast Unit, Charité Hospital Berlin, Germany; Interdisciplinary Breast Unit, Kliniken Essen Mitte, Essen, Germany.
Background: Ribociclib + endocrine therapy (ET) showed significant progression-free survival (PFS) and overall survival (OS) benefits in the MONALEESA trials in patients with HR+ /HER2 - advanced breast cancer (ABC). We report efficacy, safety, and patient-reported outcomes (PROs) across age groups, including older patients, in these trials.
Methods: Data from the MONALEESA-2, -3, and -7 trials for pre- and postmenopausal patients receiving first-line treatment for ABC were pooled and analyzed by age (<65y, 65-74y, and ≥75y).
Low-risk febrile neutropenia: does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?
Support Care Cancer
January 2025
Department of Acute Medicine, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK.
Purpose: Management of patients with low-risk febrile neutropenia in an outpatient setting guided by the MASCC score is proven to be safe and effective. Most patients on ambulatory low-risk febrile neutropenia pathways are undergoing treatment for breast cancer. Recent data has shown benefit of the addition of immune checkpoint inhibitor therapy to cytotoxic chemotherapy in the neoadjuvant setting for patients with early triple-negative breast cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!